RCL
84
-4
LYB
20
-2
LRCX
59
-3
CAT
51
-2
PFG
50
-3
TXT
73
-2
MAS
62
-2
MRK
43
2
COF
57
-2
NTRS
72
-2
HES
38
-2
TRIP
54
-4
HAL
39
-2
RHI
30
-3
VMC
78
-3
UPS
38
8
EA
54
2
OXY
45
-3
CPB
47
2
MAC
54
-3
RCL
84
-4
LYB
20
-2
LRCX
59
-3
CAT
51
-2
PFG
50
-3
TXT
73
-2
MAS
62
-2
MRK
43
2
COF
57
-2
NTRS
72
-2
HES
38
-2
TRIP
54
-4
HAL
39
-2
RHI
30
-3
VMC
78
-3
UPS
38
8
EA
54
2
OXY
45
-3
CPB
47
2
MAC
54
-3
Financhill
Back

Puma Biotechnology 10K Form

Buy
58

PBYI
Puma Biotechnology

Last Price:
$3.35
Seasonality Move:
26.36%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PBYI News And Ratings

See the #1 stock for the next 7 days that we like better than PBYI

PBYI Financial Statistics

Sales & Book Value

Annual Sales: $230.5M
Cash Flow: $3.6M
Price / Cash Flow: 5.73
Annual Sales: $1.96
Price / Book: 1.86

Profitability

EPS (TTM): 0.77000
Net Income (TTM): $38.1M
Gross Margin: $166.1M
Return on Equity: 52.9%
Return on Assets: 18.14%

Puma Biotechnology Earnings Forecast

Key Puma Biotechnology Financial Ratios

  • The Gross Profit Margin over the past 17 years for PBYI is 72.06%.
  • The Selling, General & Administrative Expenses for PBYI have been equal to 35.01% of Gross Profit Margin.
  • The Research & Development expenses have been 23.84% of Revenue.
  • The Interest Expense is 41.13% of Operating Income.
  • The Net Earning history of PBYI is 13.14% of Total Revenues.
  • Per Share Earnings over the last 17 years have been positive in 10 years.

Puma Biotechnology Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: PBYI
CUSIP: 74587V
Website: pumabiotechnology.com

Debt

Debt-to-Equity Ratio: 0.58
Current Ratio: 1.53
Quick Ratio: 1.37

Price-to-Earnings

Trailing P/E Ratio: 5.85
Forward P/E Ratio: 7.26

PBYI Technical Analysis vs Fundamental Analysis

Buy
58
Puma Biotechnology (PBYI) is a Buy

Is Puma Biotechnology a Buy or a Sell?